Jeffrey William Henderson, a director at Becton Dickinson & Co (NYSE:BDX), recently acquired 1,500 shares of the company's common stock. The purchase, which took place on February 10, 2025, was made ...
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...
3don MSN
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...
Becton, Dickinson (BD) management’s board approval to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of the organisation could reflect the ...
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic ...
Becton Dickinson BDX1.16%increase ... Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest ...
Becton Dickinson (BDX) is a global medical technology company comprised of essentially two businesses: (i) MedTech, which consists of the BD Medical (medication delivery and management solutions ...
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback